Receptos, located in San Diego California, is a wholly owned subsidiary of Celgene Corporation.


Receptos is focused on the development of therapeutic candidates for the treatment of immune and inflammatory diseases. Receptos' lead program, Ozanimod, is a sphingosine 1-phosphate 1 and 5 receptor small molecule modulator in development for immune-inflammatory indications including relapsing multiple sclerosis (RMS) and inflammatory bowel disease's (Crohn's and Ulcerative Colitis).

Receptos Opportunities Visit


Receptos Pipeline
Receptos Pipeline
200 OK


The server encountered an internal error or misconfiguration and was unable to complete your request.

Please contact the server administrator, [no address given] and inform them of the time the error occurred, and anything you might have done that may have caused the error.

More information about this error may be available in the server error log.